

Simultaneous detection and quantification of angiotensin I, II, 1-7 and 1-9 by LC-MS/MS in human plasma

Loreen Huyghebaert¹, Justine Demeuse², Elodie Grifnée¹, Philippe Massonnet¹, Jordi Farré¹, Stéphanie Peeters¹, Caroline Le Goff^{1,2}, Etienne Cavalier^{1,2} ¹ Department of Clinical Chemistry, CHU of Liège, Belgium ² Department of Clinical Chemistry, University of Liège, Belgium

O Introduction:

Recent studies showed that angiotensin-converting enzyme 2 (ACE2) is used by the severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) as a cellular entry receptor. SARS-CoV-2 causes downregulation of ACE2 leading to renin-angiotensin-aldosterone system (RAAS) major imbalance. This is an essential element of unfavorable evolution in patients with COVID-19. With lower level of ACE2, cleavage of Ang I and Ang II is decrease and therefore, Ang 1-7 and Ang 1-9 levels are decreased. The development of a quantitative method for these angiotensins is particularly interesting in the context of the prognosis/follow-up of patients with COVID-19 [1-3].

Materials and Methods: Luna Omega[®] C18 100Å core-shell Column column 100 × 2,1 mm, 1.6 µm -Extraction of 300 µL Separation/ Phenomenex of human plasma quantification Mobile A: $H_2O + 0,4\%$ FA * OISIS B: ACN + 0,4% FA phases **OASIS MAX 96-well** µelution Signal Reconstitution 100 µL Elution Electrospray – Positive ACN:H₂O (5:95), mode 0,4% FA 80 Intensity, cps Evaporation 60 ≌ %40 Gradient 20 20 10 15

Time, min

Time (Min)

O Results:

Q1 Scan – MRM – Post column flow injection

	Angiotensin I	Angiotensin II	Angiotensin 1-7	Angiotensin 1-9		
Transitions	433,1 > 619,3	524,1 > 263,2	450,4 > 647,4	395,4 > 647,5		
	DP: 50,0	DP: 50,0	DP: 50,0	DP: 50,0		
Compounds	EP: 11,0	EP: 11,0	EP: 11,0	EP: 11,0		
parameters	CXP: 22,0	CXP: 22,0	CXP: 22,0	CXP: 22,0		
	CE: 27,0	CE: 29,0	CE: 24,0	CE: 20,0		
Source	CUR: 40,0	IS: 2000,0	GS1: 50,0			
parameters	CAD: Medium	TEM: 650	GS2: 60,0			
Lower Limit of quantification		Validation steps	O Perspectives:			
	Angiotensin II	Recoveries	 Validation of the analytical method 			
7000		45-65%	 Addition of an activity of ACE2 	 Addition of an incubation step to study the activity of ACE2 BUT ACE2* is a zinc finger enzyme └→ EDTA precipitates zinc └→ ACE2 is desactivated 		
6000		Matrix effect	BUT ACE2* is a zi			
5000		No matrix effect observed	$ \longrightarrow EDTA pr$			
5000		Calibration curve	\rightarrow ACE2 is			



References:

1. Beyerstedt S, Barbosa Casaro E, Beuiloqua Rangel E – Covid 19; angiotensin-converting enzyme 2 (ACE2) expression and tissus susceptibility to SARS-COV-2 infection. European Journal of clinical Microbiology & infectious diseases 2021;40:905–919.

2. Tikellis C, Bernardi S, Burns WC – Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Current opinion in nephrology and hypertension 2011; 20:62-68.

3. Silhol F, Sarlon G, Deharo JC, Vaîsse B – Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system? Hypertension Research 2020; 43:854-856.